Aarey Drugs (AAREYDRUGS)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Debt-to-equity ratio is 0.38, indicating modest leverage and low bankruptcy risk.
• Promoter holding of 50.04% shows insider ownership and alignment with minority shareholders.
• Price-to-book of 1.82, while not cheap, is not excessive relative to book value of ₹49.48.
• Latest quarter still turned a small net profit of ₹1 crore on sales of ₹96 crore, avoiding a loss.
• Revenue base of ₹96 crore per quarter provides a platform if operations are fixed.

Concerns

• Sales growth of -27.92% and profit growth of -20.83% show a deteriorating business.
• ROE of 3.06% and ROCE of 6.38% are far below acceptable thresholds for a pharmaceutical company.
• P/E of 63.43 is unjustified given the declining earnings trajectory.
• Piotroski F-Score of 3/9 signals weak financial health and possible operational troubles.

AI Analysis

Let's look at Aarey Drugs as a business, not a ticker. At ₹89.91, the market capitalizes it at ₹218 crore. But what am I buying? The company earned a net profit of just ₹1 crore in the latest quarter on sales of ₹96 crore. Annualize that, and you get perhaps ₹4 crore—meaning I'm being asked to pay over 60 times earnings for a pharmaceutical business whose sales have fallen by nearly 28% and profits by almost 21%. That's not a recipe for wealth creation. The return on equity is a paltry 3.06%, and return on capital employed is only 6.38%. For an investor demanding a margin of safety, this fails Graham's basic tests. The Piotroski F-Score of 3 out of 9 reinforces the picture of a company under financial stress. There is no dividend to compensate while I wait. On the plus side, debt-to-equity at 0.38 is manageable, promoter holding at 50.04% is decent, and the price-to-book of 1.82 against a book value of ₹49.48 provides some cushion—but book value only matters if the business can earn an acceptable return on those assets. Right now, it isn't. This is not a stalwart, nor a fast grower. It could become a turnaround if management stabilizes sales and improves margins, but there's no evidence yet. In Buffett's language, it's a cigar butt with a few puffs left—but I prefer a business that doesn't require a rescue. I'd need to see operational stabilization, better capital allocation, and a reasonable valuation before getting interested.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer